IDiyas

For the Inventor, By the Inventor

Wuppertal, Germany

Karl Meng

USPTO Granted Patents = 24

Average Co-Inventor Count = 3.8

ph-index = 4

Forward Citations = 60(Granted Patents)


Company Filing History:

goldMedal24 out of 12,157 
 
Bayer Aktiengesellschaft
 patents

Years Active: 1976-1981

Loading Chart...
24 patents (USPTO):Explore Patents
1. 4288446 - Pyrazol-5-ones (1981-09-08),
2. 4160098 - Pyrazole derivatives (1979-07-03),
3. 4122281 - 5-Sulphonyloxy pyrazole derivatives (1978-10-24),
4. 4122280 - Pyrazole derivatives (1978-10-24),
5. 4122279 - Pyrazole derivatives (1978-10-24),
6. 4112227 - Pyrazol-5-ones (1978-09-05),
7. 4096152 - Pyrazole derivatives (1978-06-20),
8. 4081596 - Pyrazol-5-ones (1978-03-28),
9. 4076943 - 1-Substituted-3-amino-pyrazol-5-ones (1978-02-28),
10. 4069334 - Pyrazole derivatives (1978-01-17),
11. 4061653 - 1-Substituted-3-amino-pyrazol-5-ones (1977-12-06),
12. 4056533 - Pyrazol-5-ones (1977-11-01),
13. 4045571 - Pyrazol-5-ones (1977-08-30),
14. 4032646 - Pyrazol-5-ones (1977-06-28),
15. 4018890 - Pyrazol-5-one pharmaceutical compositions and methods for effecting (1977-04-19),

Title: **Innovations of Karl Meng: A Pioneer in Pharmaceutical Patents**

Introduction

Karl Meng, based in Wuppertal, Germany, is a distinguished inventor known for his substantial contributions to the field of pharmaceuticals. With a remarkable portfolio of 24 patents, Meng has established himself as a key player in the industry, particularly within Bayer Aktiengesellschaft, a leading global pharmaceutical and life sciences company.

Latest Patents

Among his latest innovations are two significant patents:

1. **Pyrazol-5-ones** - This pharmaceutical composition is particularly useful for effecting diuresis and saluresis, as well as treating hypertension in both humans and animals. The product is formulated by combining a pyrazol-5-one or a pharmaceutically acceptable nontoxic salt thereof, featuring variable R groups such as hydrogen, lower alkyl, or amino.

2. **Pyrazole derivatives** - This innovation encompasses pyrazole derivatives, which also include pharmaceutically acceptable nontoxic salts. The derivatives are defined by the formula where R may represent hydrogen, trifluoromethyl, or alkyl.

Career Highlights

Over the years, Karl Meng's dedication and expertise have led him to achieve significant milestones within Bayer Aktiengesellschaft. He has focused on innovative solutions in the pharmaceutical sector, ensuring that his work not only inspires advancement but also contributes to enhanced patient outcomes.

Collaborations

Throughout his career, Meng has collaborated with notable professionals, including Egbert Wehinger and Harald Horstmann. These partnerships have fostered an environment of creativity and progress, paving the way for groundbreaking discoveries in the realm of pharmaceuticals.

Conclusion

Karl Meng exemplifies the spirit of innovation and dedication within the pharmaceutical industry. With an impressive collection of patents and a commitment to collaboration, his work continues to shape the landscape of modern medicine. His contributions, notably in formulations like pyrazol-5-ones and pyrazole derivatives, underscore the importance of ongoing research and development in addressing pressing health challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…